GLP-1 medications

GLP-1 receptor agonists have become the dominant force in prescription drug spending, accounting for roughly 14% of all U.S. pharmaceutical expenditures in 2026. Novo Nordisk received EU approval for the first oral GLP-1 weight-loss treatment, while Pfizer and Innovent Biologics passed preliminary review for China insurance coverage and France became the first EU country to reimburse anti-obesity drugs.

The market is expanding rapidly with new formulations, coverage decisions, and global adoption, but safety signals including over 200 deaths linked to weight loss drugs in the UK and frailty risks in older adults are raising regulatory concerns worldwide.

GLP-1 medications are a class of drugs that mimic the glucagon-like peptide-1 (GLP-1) hormone, which regulates blood sugar, slows digestion, reduces appetite, and supports weight loss. They are primarily used for treating type 2 diabetes and for chronic weight management in adults with obesity or overweight conditions.

The leading GLP-1 medications include semaglutide (marketed as Ozempic for diabetes and Wegovy for weight loss, developed by Novo Nordisk) and tirzepatide (marketed as Mounjaro for diabetes and Zepbound for weight loss, developed by Eli Lilly). These drugs have transformed the treatment landscape for obesity and metabolic disorders, with clinical trials demonstrating significant weight loss and cardiovascular benefits beyond glycemic control.

The global surge in demand for GLP-1 drugs — driven primarily by their weight loss efficacy — has led to FDA-declared shortages, insurance coverage debates, and regulatory scrutiny of compounded alternatives. The SELECT trial demonstrated that semaglutide reduces cardiovascular events in patients with obesity and established cardiovascular disease, expanding the potential indications beyond diabetes and weight management alone.

Source: FDA Drug Shortages List | SELECT Trial — NEJM

GLP-1 receptor agonists are a class of medications that mimic incretin hormones to regulate blood sugar, slow gastric emptying, reduce appetite, and promote weight loss. The class includes semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda), and older agents like exenatide.

These medications have reshaped the obesity and type 2 diabetes treatment landscape, but their high list prices — roughly $1,000 per month — have created significant access and affordability challenges. Generic equivalents are not expected until at least the early 2030s due to patent protections.